NMTRC

The Neuroblastoma and Medulloblastoma Translational Research Consortium will conduct a 14-patient trial in which it will try to pinpoint treatments that best suit individual participants based on their gene expression profiles.

The trial, which has been approved by the Food and Drug Administration and will begin enrollment immediately, will use next-generation sequencing and gene expression analysis to provide information about a patient's disease state and to identify targets for therapy.